Background & AimsDaily step count measures cardiorespiratory fitness and has been associated with clinical outcomes. However, its utility in patients with cirrhosis remains largely unexplored. We aimed to investigate the association between step count, frailty metrics, and clinical outcomes in cirrhosis.MethodsAll participants underwent frailty evaluation with the liver frailty index, 6-minute walk test, and gait… Continue reading Low Daily Step Count Is Associated With a High Risk of Hospital Admission and Death in Community-Dwelling Patients With Cirrhosis
Category: Hepatology
Risk of fractures and subsequent mortality in alcohol-related cirrhosis: A nationwide population-based cohort study
Background and aimsAlcohol-related cirrhosis is linked to increased risk of fractures, but this has seldom been quantified nationally or compared against non-cirrhotic controls. Here, we determined the rate and risk of fractures and post-fracture mortality in patients with alcohol-related cirrhosis compared to individuals from the general population.MethodsIn this nationwide population-based cohort study, data were retrieved… Continue reading Risk of fractures and subsequent mortality in alcohol-related cirrhosis: A nationwide population-based cohort study
Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
National guidelines on transplant selection have adopted successful downstaging to within Milan criteria (MC) as a viable option for the treatment of hepatocellular carcinoma (HCC) before liver transplant (LT). Recurrence of HCC after LT carries a poor prognosis, and treatment modalities remain challenging.Objective To establish the 10-year outcomes of patients with HCC after LT in… Continue reading Ten-Year Outcomes of Liver Transplant and Downstaging for Hepatocellular Carcinoma
Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Predicting liver cancer riskNonalcoholic fatty liver disease (NAFLD) raises the risk of developing hepatocellular carcinoma (HCC), but this risk can be difficult to quantify and disease onset can still be difficult to catch early. Fujiwara et al. developed hepatic transcriptome and serum secretome–derived signatures to predict NAFLD-related HCC in patients over 15 years of observation.… Continue reading Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
Interleukin-27 signaling serves as an immunological checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma
AbstractWhile inflammatory mechanisms driving hepatocellular carcinoma (HCC) had been proposed, the regulators of anti-cancer immunity in HCC remain poorly understood. We found that IL-27 receptor (IL-27R) signaling promotes HCC development in vivo. High IL-27EBI3 cytokine or IL-27RA expression correlated with poor prognosis for patients with HCC. Loss of IL-27R suppressed HCC in vivo in two… Continue reading Interleukin-27 signaling serves as an immunological checkpoint for innate cytotoxic cells to promote hepatocellular carcinoma
Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
The aim of this study was to determine the impact at 5 years of sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes mellitus (T2DM) on liver histopathology and clinical features. In this retrospective study, the histological impacts at 5 years after the start of SGLT2i in NAFLD with T2DM were… Continue reading Favorable impact of long-term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5-year follow-up study
Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
BackgroundGiven the association of NAFLD with metabolic risks, a name change to MAFLD is proposed. We compared the long-term outcomes of NAFLD and MAFLD. MethodsWe included patients with fatty liver disease (FLD) from NHANES III and NHANES 2017–2018 (FLD defined as moderate to severe hepatic steatosis by ultrasound for NHANES III and as having a… Continue reading Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
Background & AimsAutoimmune hepatitis episodes have been described following SARS-CoV-2 infection and vaccination but their pathophysiology remains unclear. Here, we report the case of a 52-year-old male, presenting with bimodal episodes of acute hepatitis, each occurring 2-3 weeks after BNT162b2 mRNA vaccination and sought to identify the underlying immune correlates. The patient received first oral… Continue reading SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis
Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed
... DiscussionThis case illustrates immune-mediated hepatitis secondary to the Moderna vaccine, which on inadvertent re-exposure led to worsening liver injury with deranged synthetic function. This occurred in a well man with no other medical problems. The onset of jaundice associated with the mRNA vaccine was unusually rapid. This was also illustrated in the other cases… Continue reading Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed
